UI Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title

Assessing Nasopharyngeal and Pulmonary Adverse Events that may be Associated Certain Medications


Aspire A Postmarketing Observational Study to Assess Respiratory Tract Adverse Events in Pulmonary Arterial Hypertension Patients Treated With Tyvaso®(Treprostinil) Inhalation Solution 

Primary Outcome Measures: Describe the type and incidence of oro-/nasopharyngeal and pulmonary adverse events that may be associated with current or recent treatment with Tyvaso for PAH and with patients not treated with Tyvaso for PAH.

Please refer to www.clinicaltrials.gov for more information identifier NCT01266265

Start Date
April 11, 2011
End Date
January 21, 2015
Gender Preference
Age Group
1 - 99 years
Principal Investigator
Linda Cadaret, MD
Contact Info

Pulmonary Hypertension Program

Cynthia Larew RN 319-356-1028  pager # 2123


Internal Medicine
Enter keyword ; Heart ; inhaled prostacyclin ; observational study ; PAH ; Pulmonary Arterial Hypertension ; pulmonary hypertension ; treprostinil sodium ; Tyvaso ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.